Holen Sie sich die Stockscreener-App
109.56
1.33%
-1.48
Handel nachbörslich:
108.65
-0.91
-0.83%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$111.04
Offen:
$110.72
24-Stunden-Volumen:
11.06M
Relative Volume:
1.25
Marktkapitalisierung:
$190.38B
Einnahmen:
$44.33B
Nettoeinkommen (Verlust:
$6.50B
KGV:
29.48
EPS:
3.717
Netto-Cashflow:
$7.40B
1W Leistung:
-5.84%
1M Leistung:
-1.15%
6M Leistung:
-17.59%
1J Leistung:
-18.89%
1-Tages-Spanne:
$108.34
$110.72
1-Wochen-Bereich:
$108.34
$115.85
52-Wochen-Spanne:
$105.27
$139.15
Abbott Laboratories Stock (ABT) Company Profile
Firmenname
Abbott Laboratories
Sektor
Branche
Telefon
(224) 667-6100
Adresse
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
109.56 | 192.95B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
364.56 | 141.79B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
90.90 | 119.41B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
71.35 | 108.31B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
81.64 | 48.72B | 6.07B | 1.06B | 1.34B | 1.8063 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-10 | Eingeleitet | The Benchmark Company | Buy |
| 2025-07-18 | Hochstufung | Jefferies | Hold → Buy |
| 2025-06-16 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-10-08 | Eingeleitet | Oppenheimer | Outperform |
| 2024-09-19 | Eingeleitet | Piper Sandler | Overweight |
| 2024-07-30 | Herabstufung | Edward Jones | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2023-07-21 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | Bestätigt | Barclays | Overweight |
| 2023-04-20 | Bestätigt | Bernstein | Outperform |
| 2023-04-20 | Bestätigt | JP Morgan | Overweight |
| 2023-04-20 | Bestätigt | Raymond James | Outperform |
| 2023-04-20 | Bestätigt | UBS | Buy |
| 2023-04-20 | Bestätigt | Wolfe Research | Underperform |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2022-10-26 | Eingeleitet | Mizuho | Neutral |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-07-06 | Eingeleitet | Wolfe Research | Underperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-01-27 | Bestätigt | Credit Suisse | Outperform |
| 2022-01-27 | Bestätigt | Morgan Stanley | Overweight |
| 2022-01-27 | Bestätigt | Raymond James | Outperform |
| 2022-01-27 | Bestätigt | UBS | Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-10-27 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | Eingeleitet | Redburn | Neutral |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Neutral |
| 2021-01-28 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Outperform |
| 2020-06-01 | Herabstufung | Goldman | Neutral → Sell |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Neutral |
| 2020-02-06 | Fortgesetzt | BTIG Research | Neutral |
| 2020-01-02 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-06-13 | Bestätigt | BofA/Merrill | Buy |
| 2019-02-07 | Bestätigt | BofA/Merrill | Buy |
| 2019-01-02 | Herabstufung | Citigroup | Neutral → Sell |
| 2018-11-30 | Hochstufung | Goldman | Neutral → Buy |
| 2018-10-16 | Eingeleitet | Barclays | Overweight |
| 2018-06-27 | Eingeleitet | Bernstein | Outperform |
| 2018-01-30 | Bestätigt | Citigroup | Neutral |
| 2018-01-25 | Bestätigt | Stifel | Buy |
| 2018-01-25 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | Eingeleitet | Evercore ISI | Outperform |
| 2018-01-02 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-01-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-10-19 | Bestätigt | Stifel | Buy |
Alle ansehen
Abbott Laboratories Aktie (ABT) Neueste Nachrichten
A Look At Abbott Laboratories (ABT) Valuation After Recent Share Price Volatility - simplywall.st
Abbott IP chief: ‘Firms without AI policies scare me’ - Life Sciences Intellectual Property Review
Abbott Laboratories $ABT Shares Sold by Victory Capital Management Inc. - MarketBeat
Abbott Laboratories $ABT Shares Sold by Orion Porfolio Solutions LLC - MarketBeat
Abbott Faces Trial Over Claims Its Infant Formula Caused Bowel Disease in Premature Babies - The Indian Practitioner
Trial over Abbott Laboratories’ formula for premature babies set to begin this week - Times West Virginian
Crossmark Global Holdings Inc. Purchases 12,373 Shares of Abbott Laboratories $ABT - MarketBeat
Respiratory Disease Testing Market Global Forecast Report 2026-2032: $9.32 Bn Opportunities in Integrating Advanced Diagnostics, Leveraging Partnerships, and Enhancing Supply Resilience - GlobeNewswire Inc.
Abbott Labs to face trial on infant formula - The Economic Times
Trial over Abbott Laboratories’ formula for premature babies set to begin in Chicago this week - The Daily Gazette
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Daywatch: Trial over Abbott Laboratories’ formula for premature babies set to begin - Chicago Tribune
Abbott set to face trial over claims premature infant formula caused deadly disease - Reuters
Trial over Abbott Laboratories’ formula for premature babies set to begin in Cook County this week - Chicago Tribune
Dimensional Fund Advisors LP Purchases 169,115 Shares of Abbott Laboratories $ABT - MarketBeat
US002824BU37 Bond Price and Chart — SWB:US002824BU37 - TradingView
Abbott Laboratories EVP Cushman sells $30k in stock By Investing.com - Investing.com Australia
Abbott Laboratories EVP Cushman sells $30k in stock - Investing.com South Africa
A4EQ5K Bond Price and Chart — GETTEX:A4EQ5K - TradingView
Insider Selling: Abbott Laboratories (NYSE:ABT) EVP Sells 613 Shares of Stock - MarketBeat
Abbott Laboratories (NYSE:ABT) EVP Sells $102,288.30 in Stock - MarketBeat
Insider Selling: Abbott Laboratories (NYSE:ABT) EVP Sells 263 Shares of Stock - MarketBeat
Insider Sell: Elizabeth Cushman Sells Shares of Abbott Laborator - GuruFocus
Abbott (ABT) SVP Eric Shroff logs share sale and tax disposition - Stock Titan
Abbott Laboratories (ABT) EVP logs 4,997-share tax-withholding disposition on Form 4 - Stock Titan
Abbott (NYSE: ABT) EVP logs share sale and tax disposition - Stock Titan
Abbott (ABT) CEO Robert Ford disposes 30,308 shares for tax withholding - Stock Titan
Abbott Laboratories (ABT) EVP logs tax-withholding disposition of 8,577 shares - Stock Titan
Abbott Laboratories (NYSE: ABT) VP reports sale and tax share disposal - Stock Titan
Abbott Laboratories (ABT) CFO uses 7,441 shares to cover tax withholding - Stock Titan
Abbott (ABT) EVP logs stock sale and tax-withholding share disposal - Stock Titan
How FDA Approval of CardioMEMS Hero Remote Monitor At Abbott (ABT) Has Changed Its Investment Story - Yahoo Finance
Abbott Labs Finishes Off Suit Over Google, Meta Data Sharing - Bloomberg Law News
Abbott Laboratories Spent $20 Billion to Enter Cancer Diagnostics: Why Analysts See 60% Upside - TIKR.com
Exact Sciences Holders Back Abbott Deal As Valuation Gap Draws Focus - simplywall.st
Better Value & Growth: STE, RMD Lead Abbott Laboratories Stock - Trefis
Abbott Laboratories Stock: Is This Quiet Health Tech Giant Your Next Big US Play? - AD HOC NEWS
Abbott Beats Data Sharing Suit Over Glucose Tracking Trial - Law360
Is Abbott Laboratories (ABT) Pricing Look Attractive After Recent Share Price Weakness? - simplywall.st
[144] ABBOTT LABORATORIES SEC Filing - Stock Titan
Abbott (ABT) Stock Sinks As Market Gains: Here's Why - Yahoo Finance
Abbott Laboratories stock underperforms Monday when compared to competitors - MarketWatch
Futures Contracts for Abbott Laboratories Futures - TradingView
NICE recommends leadless pacemakers to treat slow heart rhythms - BioWorld MedTech
2 Reasons to Like ABT and 1 to Stay Skeptical - StockStory
Abbott wins FDA approval for updated heart failure monitoring device - MedTech Dive
Abbott Laboratories (NYSE:ABT) Emerges as a Top Dividend Stock with Strong Fundamentals - ChartMill
Fisher Asset Management LLC Raises Stock Position in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Sold by Laurel Wealth Advisors LLC - MarketBeat
Abbott Laboratories stock forecast for 2030: Exact Sciences acquisition reshapes growth outlook toward $180 - Traders Union
Antibiotics Market - GlobeNewswire Inc.
Finanzdaten der Abbott Laboratories-Aktie (ABT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Abbott Laboratories-Aktie (ABT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Salvadori Daniel Gesua Sive | EVP AND GROUP PRESIDENT |
Mar 02 '26 |
Sale |
115.58 |
885 |
102,288 |
146,377 |
| Morrone Louis H. | EXECUTIVE VICE PRESIDENT |
Mar 02 '26 |
Sale |
115.58 |
1,144 |
132,224 |
76,843 |
| Moreland Mary K | EXECUTIVE VICE PRESIDENT |
Mar 02 '26 |
Sale |
115.58 |
613 |
70,851 |
104,291 |
| MCCOY JOHN A. JR. | VICE PRESIDENT AND CONTROLLER |
Mar 02 '26 |
Sale |
115.58 |
585 |
67,614 |
24,628 |
| Cushman Elizabeth C. | EVP, GC AND SECRETARY |
Mar 02 '26 |
Sale |
115.58 |
263 |
30,398 |
38,573 |
1.60%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):